BCTXW
BriaCell Therapeutics Corp.
Price Chart
No historical data available
Latest Quote
$0.00
-0.00 (-57.14%)
Current Price
| Previous Close | $0.00 |
| Open | $0.06 |
| Day High | $0.00 |
| Day Low | $0.00 |
| Volume | 186,380 |
Stock Information
| Cash Equivalents | $10.18M |
| Net Income | $-28.71M |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Income | $-28.71M |
| Book/sh | $5.30 |
Financial Ratios
| Quick Ratio | 3.42 |
| Current Ratio | 3.42 |
Returns & Margins
| ROA | -161.64% |
| ROE | -444.07% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | 0.00 |
Analyst Data
| Recommendation | none |
Technical Indicators
| Shares Float | 1.67M |
| Volatility | 2.03 |
Performance History
| YTD | +0.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
No history data available. Data will be fetched automatically.
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
đ° Latest News
BriaCell Presenting Final Phase 2, Ongoing Phase 3 Data at ASCO Meeting
MT Newswires âĸ 2026-06-01T13:57:47ZBriaCell Therapeutics Completes Manufacturing Bria-PROS+ Clinical Supplies
MT Newswires âĸ 2026-05-14T12:45:41ZBriaCell Says FDA Clears Way For Bria-BRES+ Phase 1/2a Study
MT Newswires âĸ 2026-05-06T11:56:21ZZacks.com featured highlights include Groupon, BriaCell Therapeutics and InnovAge Holding
Zacks âĸ 2025-10-28T08:01:00Z
Top 3 Earnings Acceleration Buys for November
Zacks âĸ 2025-10-27T19:05:00Z
BriaCell Adds Three Cancer Centres to Phase 3 Study, Works With MSK Accelerator to Advance Bria-OTS+
MT Newswires âĸ 2025-10-21T12:16:21ZHere's Why We're A Bit Worried About BriaCell Therapeutics' (TSE:BCT) Cash Burn Situation
Simply Wall St. âĸ 2025-06-25T12:11:35Z
BriaCell Up in U.S. Pre-market, as Data Safety Board Review Recommends Phase 3 Study Continues
MT Newswires âĸ 2025-06-24T12:52:14Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $33,330,076 | $23,272,264 | $15,285,553 | $6,972,344 |
| Other Income Expense | $28,110,510 | $2,078,657 | $-11,689,102 | $-6,768,451 |
| Net Non Operating Interest Income Expense | $288,018 | $891,213 | $135,752 | $-75,405 |
| Operating Expense | $33,330,076 | $23,272,264 | $15,285,553 | $6,972,344 |
| General And Administrative Expense | $6,152,269 | $7,935,626 | $7,267,452 | $4,955,136 |
| Interest Expense | - | $0 | $979 | $78,554 |
| Interest Expense Non Operating | - | $0 | $979 | $78,554 |
| Total Other Finance Cost | - | - | $11,658,372 | $4,448,957 |
| Other Operating Expenses | - | - | $-3,388 | $-3,691 |
| Rent Expense Supplemental | - | - | - | $11,939 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-4,791,466 | $-20,302,394 | $-26,838,903 | $-13,816,200 |
| Net Interest Income | $288,018 | $891,213 | $135,752 | $-75,405 |
| Interest Income | $288,018 | $891,213 | $136,731 | $3,149 |
| Normalized Income | $-33,008,486 | $-22,381,051 | $-15,149,801 | $-7,047,749 |
| Net Income From Continuing And Discontinued Operation | $-4,791,466 | $-20,302,394 | $-26,838,903 | $-13,816,200 |
| Total Operating Income As Reported | $-33,330,076 | $-23,272,264 | $-15,288,941 | $-6,973,498 |
| Net Income Common Stockholders | $-4,791,466 | $-20,302,394 | $-26,838,903 | $-13,816,200 |
| Net Income | $-4,791,466 | $-20,302,394 | $-26,838,903 | $-13,816,200 |
| Net Income Including Noncontrolling Interests | $-4,931,548 | $-20,302,394 | $-26,838,903 | $-13,816,200 |
| Net Income Continuous Operations | $-4,931,548 | $-20,302,394 | $-26,838,903 | $-13,816,200 |
| Pretax Income | $-4,931,548 | $-20,302,394 | $-26,838,903 | $-13,816,200 |
| Earnings From Equity Interest | $-106,510 | $0 | - | - |
| Interest Income Non Operating | $288,018 | $891,213 | $136,731 | $3,149 |
| Operating Income | $-33,330,076 | $-23,272,264 | $-15,285,553 | $-6,972,344 |
| Special Income Charges | - | - | $0 | $-141,703 |
| Depreciation Amortization Depletion Income Statement | - | - | - | $15,254 |
| Depreciation And Amortization In Income Statement | - | - | - | $15,254 |
| Amortization Of Intangibles Income Statement | - | - | - | $15,254 |
| Depreciation Income Statement | - | - | - | $15,254 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-33,064,671 | $-25,335,650 | $-15,133,550 | $-6,953,939 |
| Total Unusual Items | $28,217,020 | $2,078,657 | $-11,689,102 | $-6,768,451 |
| Total Unusual Items Excluding Goodwill | $28,217,020 | $2,078,657 | $-11,689,102 | $-6,768,451 |
| Reconciled Depreciation | $83,897 | $15,271 | $15,272 | $15,256 |
| EBITDA (Bullshit earnings) | $-4,847,651 | $-23,256,993 | $-26,822,652 | $-13,722,390 |
| EBIT | $-4,931,548 | $-23,272,264 | $-26,837,924 | $-13,737,646 |
| Diluted NI Availto Com Stockholders | $-4,791,466 | $-20,302,394 | $-26,838,903 | $-13,816,200 |
| Minority Interests | $140,082 | $0 | - | - |
| Gain On Sale Of Security | $28,217,020 | $2,078,657 | $-11,689,102 | $-6,626,748 |
| Research And Development | $27,177,807 | $15,336,638 | $8,021,489 | $2,020,899 |
| Selling General And Administration | $6,152,269 | $7,935,626 | $7,267,452 | $4,955,136 |
| Other Gand A | $6,152,269 | $7,935,626 | $7,267,452 | $4,955,136 |
| Other Special Charges | - | - | - | $141,703 |
| Amortization | - | - | - | $15,254 |
| Insurance And Claims | - | - | - | $318,034 |
| Rent And Landing Fees | - | - | - | $11,939 |
| Salaries And Wages | - | - | - | $2,147,392 |
Fetched: 2026-02-11
Balance Sheet (Annual)
| Metric | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-2,582,206 | $-3,992,249 | $10,098,593 | $27,426,111 |
| Total Assets | $5,872,261 | $27,163,577 | $42,577,041 | $58,043,762 |
| Total Non Current Assets | $2,218,407 | $215,070 | $230,341 | $245,612 |
| Non Current Prepaid Assets | $1,211,946 | $0 | - | - |
| Goodwill And Other Intangible Assets | $199,796 | $215,068 | $230,339 | $245,610 |
| Other Intangible Assets | $199,796 | $215,068 | $230,339 | $245,610 |
| Current Assets | $3,653,854 | $26,948,507 | $42,346,700 | $57,798,150 |
| Prepaid Assets | $1,422,749 | $4,979,673 | $1,280,945 | $516,891 |
| Receivables | $1,369,016 | $717,742 | $24,103 | $12,574 |
| Other Receivables | $1,369,016 | $717,742 | - | - |
| Cash Cash Equivalents And Short Term Investments | $862,089 | $21,251,092 | $41,041,652 | $57,268,685 |
| Cash And Cash Equivalents | $862,089 | $21,251,092 | $41,041,652 | $57,268,685 |
| Accounts Receivable | - | $18,873 | $24,103 | $12,574 |
| Cash Financial | - | - | - | $57,268,685 |
| Debt | ||||
| Total Debt | - | - | - | $25,986 |
| Long Term Debt And Capital Lease Obligation | - | - | - | $25,986 |
| Long Term Debt | - | - | - | $25,986 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $8,557,193 | $30,940,758 | $32,248,109 | $30,372,041 |
| Total Non Current Liabilities Net Minority Interest | $1,096,036 | $29,139,301 | $31,307,022 | $29,815,246 |
| Derivative Product Liabilities | $1,096,036 | $29,139,301 | $31,307,022 | $29,789,260 |
| Current Liabilities | $7,461,157 | $1,801,457 | $941,087 | $556,795 |
| Payables And Accrued Expenses | $7,461,157 | $1,801,457 | $941,087 | $556,795 |
| Payables | $7,170,781 | $1,123,739 | $463,280 | $295,083 |
| Accounts Payable | $7,170,781 | $1,123,739 | $463,280 | $214,116 |
| Other Payable | - | - | - | $80,967 |
| Equity | ||||
| Common Stock Equity | $-2,382,410 | $-3,777,181 | $10,328,932 | $27,671,721 |
| Total Equity Gross Minority Interest | $-2,684,932 | $-3,777,181 | $10,328,932 | $27,671,721 |
| Stockholders Equity | $-2,382,410 | $-3,777,181 | $10,328,932 | $27,671,721 |
| Other Equity Interest | $11,033,557 | $7,421,950 | - | $18,371,605 |
| Gains Losses Not Affecting Retained Earnings | $-138,684 | $-138,684 | $-138,684 | $-138,684 |
| Other Equity Adjustments | $-138,684 | $-138,684 | $-138,684 | $-138,684 |
| Retained Earnings | $-85,443,697 | $-80,652,231 | $-60,349,837 | $-29,141,897 |
| Long Term Equity Investment | $418,490 | $0 | - | - |
| Other | ||||
| Ordinary Shares Number | $121,897 | $106,544 | $103,453 | $101,797 |
| Share Issued | $121,897 | $106,544 | $103,453 | $101,797 |
| Tangible Book Value | $-2,582,206 | $-3,992,249 | $10,098,593 | $27,426,111 |
| Invested Capital | $-2,382,410 | $-3,777,181 | $10,328,932 | $27,697,707 |
| Working Capital | $-3,807,303 | $25,147,050 | $41,405,613 | $57,241,355 |
| Total Capitalization | $-2,382,410 | $-3,777,181 | $10,328,932 | $27,697,707 |
| Minority Interest | $-302,522 | $0 | - | - |
| Capital Stock | $72,166,414 | $69,591,784 | $65,589,293 | $54,774,172 |
| Common Stock | $72,166,414 | $69,591,784 | $65,589,293 | $54,774,172 |
| Current Accrued Expenses | $290,376 | $677,718 | $477,807 | $261,712 |
| Investments And Advances | $418,490 | $2 | $2 | $2 |
| Investmentsin Subsidiariesat Cost | $418,490 | $0 | - | - |
| Net PPE | $388,175 | $0 | - | - |
| Accumulated Depreciation | $-68,626 | $0 | - | - |
| Gross PPE | $456,801 | $0 | - | - |
| Other Properties | $456,801 | - | - | - |
| Additional Paid In Capital | - | $7,421,950 | $5,228,160 | $2,178,130 |
Fetched: 2026-02-11
Cash Flow Statement (Annual)
| Metric | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-24,582,929 | $-23,744,860 | $-12,484,376 | $-7,750,188 |
| Operating Activities | ||||
| Operating Cash Flow | $-24,126,128 | $-23,744,860 | $-12,484,376 | $-7,750,188 |
| Cash Flow From Continuing Operating Activities | $-24,126,128 | $-23,744,860 | $-12,484,376 | $-7,750,188 |
| Operating Gains Losses | $-28,135,962 | $-2,119,530 | $11,658,372 | $4,488,864 |
| Investing Activities | ||||
| Capital Expenditure | $-456,801 | - | - | - |
| Investing Cash Flow | $-681,801 | $0 | - | $0 |
| Cash Flow From Continuing Investing Activities | $-681,801 | $0 | - | $0 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-47,294 | $-10,171,732 | $0 |
| Issuance Of Capital Stock | $4,418,926 | $4,000,000 | $0 | $51,622,337 |
| Financing Cash Flow | $4,418,926 | $3,954,300 | $-3,742,657 | $64,997,624 |
| Cash Flow From Continuing Financing Activities | $4,418,926 | $3,954,300 | $-3,742,657 | $64,997,624 |
| Net Common Stock Issuance | $4,418,926 | $3,952,706 | $-10,171,732 | $51,622,337 |
| Common Stock Issuance | $4,418,926 | $4,000,000 | $0 | $51,622,337 |
| Net Other Financing Charges | - | - | $-80,693 | - |
| Other | ||||
| End Cash Position | $862,089 | $21,251,092 | $41,041,652 | $57,268,685 |
| Beginning Cash Position | $21,251,092 | $41,041,652 | $57,268,685 | $21,249 |
| Changes In Cash | $-20,389,003 | $-19,790,560 | $-16,227,033 | $57,247,436 |
| Proceeds From Stock Option Exercised | $0 | $1,594 | $6,509,768 | $13,705,685 |
| Common Stock Payments | $0 | $-47,294 | $-10,171,732 | $0 |
| Net Business Purchase And Sale | $-225,000 | $0 | - | - |
| Purchase Of Business | $-225,000 | $0 | - | - |
| Net PPE Purchase And Sale | $-456,801 | $0 | - | - |
| Purchase Of PPE | $-456,801 | $0 | - | - |
| Change In Working Capital | $7,053,407 | $-3,531,997 | $-391,292 | $-2,282,106 |
| Change In Payables And Accrued Expense | $5,659,703 | $860,370 | $384,292 | $-2,191,063 |
| Change In Accrued Expense | $-387,339 | $199,911 | $135,128 | $-785,399 |
| Change In Payable | $6,047,042 | $660,459 | $249,164 | $-1,405,664 |
| Change In Account Payable | $6,047,042 | $660,459 | $249,164 | $-1,405,664 |
| Change In Prepaid Assets | $2,126,282 | $-4,397,597 | $-764,054 | $-100,984 |
| Change In Receivables | $-732,578 | $5,230 | $-11,530 | $9,941 |
| Stock Based Compensation | $1,804,078 | $2,193,790 | $3,074,584 | $1,968,226 |
| Depreciation Amortization Depletion | $83,897 | $15,271 | $15,272 | $15,256 |
| Depreciation And Amortization | $83,897 | $15,271 | $15,272 | $15,256 |
| Amortization Cash Flow | $15,271 | $15,271 | $15,272 | - |
| Amortization Of Intangibles | $15,271 | $15,271 | $15,272 | - |
| Depreciation | $68,626 | $0 | - | - |
| Earnings Losses From Equity Investments | $106,510 | $0 | - | - |
| Gain Loss On Investment Securities | $-28,242,472 | $-2,119,530 | $11,658,372 | $4,448,957 |
| Net Income From Continuing Operations | $-4,931,548 | $-20,302,394 | $-26,838,903 | $-13,816,200 |
| Repayment Of Debt | - | - | $0 | $-546,108 |
| Issuance Of Debt | - | - | $0 | $215,710 |
| Net Issuance Payments Of Debt | - | - | $0 | $-330,398 |
| Net Short Term Debt Issuance | - | - | $0 | $-330,398 |
| Short Term Debt Payments | - | - | $0 | $-546,108 |
| Short Term Debt Issuance | - | - | $0 | $215,710 |
| Other Non Cash Items | - | - | $-2,409 | $1,875,772 |
| Effect Of Exchange Rate Changes | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $-93,935 |
| Long Term Debt Payments | - | - | - | $-309,645 |
| Long Term Debt Issuance | - | - | - | $215,710 |
| Net Investment Purchase And Sale | - | - | - | $0 |
| Net Foreign Currency Exchange Gain Loss | - | - | - | $0 |
Fetched: 2026-02-11